SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2021

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Schedule of estimated useful lives of property, plant and equipment

Production equipment	3 to 13 years
Office furniture and equipment	3 to 10 years
Buildings	39 years
Building improvements	15 years

Schedule of significant customers

	Three Months Ended			Three Months Ended			Six Months Ended			Six Months Ended
	June 30, 2021			June 30, 2020			June 30, 2021			June 30, 2020
Number of significant customers		1			4			1			2
Aggregate dollar amount of net sales to significant customers	$	27.4 million		$	6.0 million		$	65.1 million		$	6.9 million
Percentage of net sales to significant customers		64.4	%		52.1	%		70.4	%		30.2	%

Schedule of disaggregated information of revenue recognized from contracts with customers and licensing fees

	For the three months ended June 30, 2020:
			Blood						Total
			Collection		EasyPoint®		Other		Product
Geographic Segment	Syringes		Products		Needles		Products		Sales
U.S. sales	$	7,492,387		235,720		1,656,712		24,976	$	9,409,795
North and South America sales (excluding U.S.)		1,561,242		5,300		—		377,348		1,943,890
Other international sales		216,160		1,850		—		2,150		220,160
Total	$	9,269,789	$	242,870	$	1,656,712	$	404,474	$	11,573,845

	For the six months ended June 30, 2021:
			Blood						Total
			Collection		EasyPoint®		Other		Product
Geographic Segment	Syringes		Products		Needles		Products		Sales
U.S. sales (excluding U.S. government)	$	19,652,047	$	1,030,826	$	2,971,268	$	28,946	$	23,683,087
Sales to U.S. government		65,140,200		—		—		—		65,140,200
North and South America sales (excluding U.S.)		2,293,328		—		56,848		109,440		2,459,616
Other international sales		771,836		62,640		450,440		2,850		1,287,766
Total	$	87,857,411	$	1,093,466	$	3,478,556	$	141,236	$	92,570,669

	For the six months ended June 30, 2020:
			Blood						Total
			Collection		EasyPoint®		Other		Product
Geographic Segment	Syringes		Products		Needles		Products		Sales
U.S. sales	$	14,465,322	$	815,843	$	2,422,572	$	42,855	$	17,746,592
North and South America sales (excluding U.S.)		3,616,026		8,000		1,496		1,064,768		4,690,290
Other international sales		330,990		3,590		—		4,600		339,180
Total	$	18,412,338	$	827,433	$	2,424,068	$	1,112,223	$	22,776,062

Schedule of earnings per share

	Three Months Ended		Three Months Ended		Six Months Ended		Six Months Ended
	June 30, 2021		June 30, 2020		June 30, 2021		June 30, 2020
Net income	$	10,662,125	$	3,766,113	$	28,618,009	$	4,088,886
Preferred stock dividend requirements		(59,170)		(174,148)		(124,108)		(348,291)
Income applicable to common shareholders	$	10,602,955	$	3,591,965	$	28,493,901	$	3,740,595
Weighted average common shares outstanding		34,000,771		32,789,047		33,984,271		32,735,126
Weighted average common and common equivalent shares outstanding — assuming dilution		34,376,335		32,985,381		34,365,092		32,856,003
Basic earnings per share	$	0.31	$	0.11	$	0.84	$	0.11
Diluted earnings per share	$	0.31	$	0.11	$	0.83	$	0.11

Schedule of share-based compensation costs

	Three Months Ended		Three Months Ended		Six Months Ended		Six Months Ended
	June 30, 2021		June 30, 2020		June 30, 2021		June 30, 2020
Cost of Sales	$	—	$	—	$	—	$	—
Sales and Marketing		—		—		—		—
Research and development		—		—		—		—
General and administrative		1,345,915		—		1,345,915		—
	$	1,345,915	$	—	$	1,345,915	$	—